1-3 of 3
Yanping Hu
Close
Sort by
Journal Articles

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome

Clinical Trials & Observations
Raffaele Badolato, Laia Alsina, Antoine Azar, Yves Bertrand, Audrey A. Bolyard, David Dale, Àngela Deyà-Martínez, Kathryn E. Dickerson, Navid Ezra, Henrik Hasle, Hyoung Jin Kang, Sorena Kiani-Alikhan, Taco W. Kuijpers, Alexander Kulagin, Daman Langguth, Carina Levin, Olaf Neth, Peter Olbrich, Jane Peake, Yulia Rodina, Caroline E. Rutten, Anna Shcherbina, Teresa K. Tarrant, Matthias G. Vossen, Christian A. Wysocki, Andrea Belschner, Gary J. Bridger, Kelly Chen, Susan Dubuc, Yanping Hu, Honghua Jiang, Sunny Li, Rick MacLeod, Murray Stewart, Arthur G. Taveras, Tina Yan, Jean Donadieu
Journal: Blood
Blood (2024) 144 (1): 35–45.
https://doi.org/10.1182/blood.2023022658
Published: 2024
Includes: Supplemental data
Journal Articles

Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

David C. Dale, Frank Caleb Firkin, Audrey Anna Bolyard, Weihua Tang, Honghua Jiang, Richard MacLeod, Diego Cadavid, Yanping Hu
Journal: Blood
Blood (2021) 138 (Supplement 1): 1121.
https://doi.org/10.1182/blood-2021-145759
Published: 2021
Journal Articles

Treatment with the CXCR4 Antagonist AMD3100 Enhances Antibody Mediated Killing in Disseminated Lymphoma Models.

William Siders, Yanping Hu, Matthew Gale, Gary Jacques, Robert Fogle, Jacqueline Shields, Carrie Garron, Johanne Kaplan
Journal: Blood
Blood (2009) 114 (22): 2717.
https://doi.org/10.1182/blood.V114.22.2717.2717
Published: 2009